ArticleMolecular psychiatry2026
Global burden of autism spectrum disorders among population aged 70 years and older from 1990-2021, with projections to 2040: findings from the Global Burden of Disease Study 2021.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- JUND-driven stress-responsive astrocytes promote neuronal apoptosis via enhanced gap junction signaling in autism spectrum disorder.Molecular autism · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorders (ASD) is a lifelong neurodevelopmental condition that negatively affects older adults, yet it receives minimal priority and limited attention in research and healthcare services for this population. Using data from Global Burden of Diseases, Injuries, and Risk Factors Study 2021, we estimated the prevalence and disability-adjusted life-years (DALYs) of ASD among population aged ≥70 years globally from 1990-2021, with projections to 2040. Decomposition analysis was conducted. Globally, the number of ASD cases among individuals aged ≥70 years increased from 894.7 thousand in 1990 to 2478.9 thousand in 2021, corresponding to an increase of 177.1%, with population growth contributing to the largest increase, followed by increased age-specific prevalence rates. It is projected that by 2040, the number of cases will reach 5150.9 thousand worldwide, accounting for 864.7 thousand DALYs. Between 1990 and 2021, the prevalence rate of ASD among the older population increased by 13.2%, projecting to increase steadily by 2040. Males had a higher prevalence rate of ASD in 2021 (773.6 versus 287.8 per 100,000 people) than females. High sociodemographic index (SDI) countries had the highest rate and the greatest increase. Similar trend patterns were observed in the number of DALYs and DALY rates. To address this overlooked but increasingly severe challenge, more attention and timely development of effective interventions and management services are needed. High SDI countries should focus on developing effective intervention and treatment strategies, while middle and low SDI countries need to improve screening and diagnostic capacities and public awareness of ASD.
Indexed as
Identifiers
40877468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.